APA (7th ed.) Citation

Y, O., N, T., Y, M., S, Y., T, K., A, K., . . . K, H. (2026). Outcomes of combination therapy with nusinersen, onasemnogene abeparvovec, and risdiplam over 3.5 years in a patient with prenatally diagnosed spinal muscular atrophy type 0: A case report. Brain & development, 48(2), 104520. https://doi.org/10.1016/j.braindev.2026.104520

Chicago Style (17th ed.) Citation

Y, Okubo, et al. "Outcomes of Combination Therapy with Nusinersen, Onasemnogene Abeparvovec, and Risdiplam over 3.5 years in a Patient with Prenatally Diagnosed Spinal Muscular Atrophy Type 0: A Case Report." Brain & Development 48, no. 2 (2026): 104520. https://doi.org/10.1016/j.braindev.2026.104520.

MLA (9th ed.) Citation

Y, Okubo, et al. "Outcomes of Combination Therapy with Nusinersen, Onasemnogene Abeparvovec, and Risdiplam over 3.5 years in a Patient with Prenatally Diagnosed Spinal Muscular Atrophy Type 0: A Case Report." Brain & Development, vol. 48, no. 2, 2026, p. 104520, https://doi.org/10.1016/j.braindev.2026.104520.